Omnicell, Inc.
NASDAQ:OMCLMedical - Healthcare Information Services
-$0.58 today
- Market cap
- $1.59B
- Beta
- 0.96
- P/E (TTM)
- 84.1
- EPS (TTM)
- $0.45
Volume 0.34M
Average 0.57M
OMCL EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Omnicell, Inc.NASDAQ: OMCL
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA growth accelerates
Q1 FY2026 EBITDA of $35.48M rose 180.3% year over year, ahead of the -1.1% change in trailing-twelve-month EBITDA. Sequentially, it rose 39.6% from the prior quarter. Over 3 fiscal years it compounded at +1.7% a year.
Context
- EBITDA amounted to 8.6% of revenue in FY2025, down 2.2 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of $226.23M (+122.1%) for the fiscal year ending Dec 2026, a step up from the -15.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $35.48M+39.6% QoQ
- Last fiscal yearDec 2025
- $101.87M-15.0% YoY
- LTMMar 2026
- $124.69M-1.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +180.3% | +48.7% | -131.6 pp |
| 1 year | -15.0% | +122.1% | +137.1 pp |
| 3-year CAGR | +1.7% | +27.0% | +25.3 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 101.87M USD
- Year-over-year change
- -15.0%
- 4-year CAGR
- -12.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 101.87M | -15.0% |
| FY2024 | 2024-12-31 | 119.87M | +49.9% |
| FY2023 | 2023-12-31 | 79.98M | -17.4% |
| FY2022 | 2022-12-31 | 96.85M | -44.1% |
| FY2021 | 2021-12-31 | 173.33M | — |
EBITDA vs competitors
How OMCL compares with its peers on the latest reported figures
- OMCL's LTM Mar 2026 EBITDA of $124.69M is the 4th highest of the 11 companies compared; the peer median is $49.87M.
- Its year-over-year change of -1.1% is the lowest of 11, against a peer median of +75.1%.
- EBITDA amounts to 10.2% of revenue for OMCL, versus a peer median of 8.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $173.34M | +1.2% | +41.4% | 22.0% | |
| LTM Mar 2026 | $162.81M | +26.3% | +6.5% | 4.6% | |
| LTM Jun 2026 | $127.06M | +36.3% | +56.8% | 9.7% | |
| LTM Mar 2026 | $124.69M | -1.1% | +1.7% | 10.2% | |
| LTM Jun 2026 | $116.08M | +3.1% | +18.3% | 18.4% | |
| LTM Mar 2026 | $57.31M | +74.6% | — | 2.3% | |
| LTM Apr 2026 | $42.42M | +563.3% | — | 8.6% | |
| LTM Sep 2026 | $37.56M | +221.9% | — | 6.1% | |
| LTM Mar 2026 | $491K | +101.7% | — | 0.2% | |
| LTM Mar 2026 | -$3.71M | +78.9% | — | 7.7% | |
| LTM Sep 2026 | -$41.03M | +75.6% | — | 15.2% | |
| Peer median (excluding OMCL) | $49.87M | +75.1% | +29.8% | 8.1% | |
Competitors are the stored peer set for OMCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.13B | 1.3B | 1.15B | 1.11B | 1.18B |
| Cost of Revenue | 577.37M | 706.96M | 647.18M | 641.24M | 676.8M |
| Gross Profit | 554.65M | 588.99M | 499.93M | 471M | 508.04M |
| Gross Margin | 49.0% | 45.4% | 43.6% | 42.3% | 42.9% |
| Research & Development | 75.72M | 104.97M | 93.29M | 90.41M | 87.74M |
| Selling, General & Admin | 389.43M | 486.34M | 425.97M | 380.25M | 408.64M |
| Operating Expenses | 465.15M | 591.31M | 519.26M | 470.67M | 496.38M |
| Depreciation & Amortization | 84.93M | 99.17M | 95.56M | 89.76M | 86.63M |
| EBITDA | 173.33M | 96.85M | 79.98M | 119.87M | 101.87M |
| EBITDA Margin | 15.3% | 7.5% | 7.0% | 10.8% | 8.6% |
| Operating Income | 89.51M | (2.32M) | (19.33M) | 337K | 11.67M |
| Operating Margin | 7.9% | -0.2% | -1.7% | 0.0% | 1.0% |
| Interest Income | 0 | 0 | 14.76M | 24.9M | 11.9M |
| Interest Expense | 22.39M | 130K | 0 | 4.53M | 3.91M |
| Other Income / Expenses | (23.5M) | (130K) | (779K) | 25.26M | (340K) |
| Income Before Tax | 66.01M | (2.45M) | (20.11M) | 25.59M | 11.33M |
| Pre-Tax Margin | 5.8% | -0.2% | -1.8% | 2.3% | 1.0% |
| Income Tax Expense | (11.84M) | (8.1M) | 263K | 13.06M | 9.27M |
| Net Income | 77.85M | 5.65M | (20.37M) | 12.53M | 2.05M |
| Net Margin | 6.9% | 0.4% | -1.8% | 1.1% | 0.2% |
| EPS (Basic) | 1.79 | 0.13 | (0.45) | 0.27 | 0.04 |
| EPS (Diluted) | 1.62 | 0.12 | (0.45) | 0.27 | 0.04 |
| Weighted Avg Shares | 43.48M | 44.4M | 45.21M | 46.05M | 45.97M |
| Weighted Avg Shares (Diluted) | 47.94M | 45.89M | 45.21M | 46.26M | 46.36M |
Omnicell, Inc.
NASDAQ:OMCL
Intrinsic Alpha fair value
Locked
Current Price
$34.66
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.